The Reporting Recommendations for Tumor Marker Prognostic Studies guidelines [11]. The primary breast tumors were from patients with detailed clinical follow-up as previously described [12-14]. ER protein status was determined by routine ligand-binding assays or enzyme immunoassays [15], and ESR1, ESR2, and PGR mRNA status wasTissue processing, RNA isolation, cDNA synthesis, and quantitative RT-PC
Ijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Geert Grooteplein 28, Nijmegen, 6525 GA, The Netherlands. 3 Department of Radiation Oncology and Department of Laboratory Medicine, Radboud University Nijmegen Medical Centre, Geert Grooteplein 32, Nijmegen, 6525 GA, The Netherlands.Authors' contributions AMS participated in the study design, collected laborato
Early breast cancer. The patients described in thisSieuwerts et al. Breast Cancer Research 2010, 12:R103 http://breast-cancer-research.com/content/12/6/RPage 7 ofTable 3 Disease-free survival, metastasis-free survival, and overall survival as a function of continuous DC-SCRIPT in lymph node-negative diseaseAssociation with continuous DC-SCRIPT Cohort Lymph node-negative ESR1 mRNA-negativea ESR1 mR
Ariable in subgroups of tumors stratified by steroid hormone receptor status and tumor size (Table 3 and Figure 1). Subdividing the 837 primary LNN tumors into ESR1-positive and -negative [14] showed that increasing levels of DCSCRIPT were, in univariate and multivariable analyses, associated with good prognosis only for the patients with ESR1-positive tumors. Subdividing these LNN tumors at the m
Nalyses, and provided critical revision of the manuscript. PNS provided critical revision of the manuscript and participated in the study design. VdW and AvG performed the laboratory work and provided critical revision of the manuscript. JAF and JWMM participated in the study design, provided the study material and clinical information, and provided critical revision of the manuscript. GJA partici
Nalyses, and provided critical revision of the manuscript. PNS provided critical revision of the manuscript and participated in the study design. VdW and AvG performed the laboratory work and provided critical revision of the manuscript. JAF and JWMM participated in the study design, provided the study material and clinical information, and provided critical revision of the manuscript. GJA partici
Ed two models. Model 1 was constructed using variables with P
Ly, 681 cases (91.2 ) were ductal carcinomas and 66 cases (8.8 ) were of other types (lobular, medullary, mucinous, papillary, or tubular carcinoma). Mean age at inclusion time was 45.9 ?9.8 (mean ?SD) years and 31.3 were postmenopausal women (Table 1). Most baseline characteristics did not differ between the ER/PR-negative and -positive groups (all Ps > 0.05; Table 1, some data not shown). Howev